Torrey Pines Investment, Inc., founded in 2002, is a specialty life-science investment company located in San Diego. Torrey Pines has a team of investment professionals with extensive experience in entrepreneurship, venture capital and operations. Our firm has created biopharma incubators investing in early development stage assets from international pharma and biotech partners in CNS, oncology, and virology area to bring them to commercial success through pharma partnering and M&A. Our philosophy centers on maximizing the potential for capital gains and confining the risk of loss by:

1. potential positioning as first on the market or best on the market therapy or potential for generating value through combination with such positions,
2. the value orientation starting at pre-clinical candidate level exiting at clinical proof of concept,
3. stream lining the development through an embedded collaboration with co-owned global CRO network based on aligned incentives,
4. minimizing the fixed cost through managing asset portfolios by proven professional drug hunters and drug developer management teams,
5. maintaining a pro-active pharma partner oriented exit strategy through call options and other mechanisms of early partner participation.

We are committed to capitalizing on the unique opportunities in biotech and pharma, where we can add value in development or regulatory strategy by utilizing resources of our portfolio CRO companies. We seek to leverage our industry knowledge, network of industry and financial contacts, and internal resources to assist our portfolio management in developing and executing their business strategy. Our bottom line is to help our companies achieve growth, build value and realize wealth.

Torrey Pines Investment will lead, co-lead or take a membership role in an investing syndicate. We are looking for an expected POC on the investment within 3 years. We assist our portfolio companies with both product and corporate development by leveraging our expertise in drug discovery, including pre-clinical studies, clinical studies and manufacturing, as well as regulatory affairs.

Our executive team systematically offers extensive market and drug development recommendations , as well as financial, operational and strategic advice, to our portfolio companies through regular communications.